title: Age-related accumulation of the advanced glycation endproduct pentosidine in human articular cartilage aggrecan: the use of pentosidine levels as a quantitative measure of protein turnover.
abstract: During aging, non-enzymatic glycation results in the formation and accumulation of the advanced glycation endproduct pentosidine in long-lived proteins, such as articular cartilage collagen. In the present study, we investigated whether pentosidine accumulation also occurs in cartilage aggrecan. Furthermore, pentosidine levels in aggrecan subfractions of different residence time were used to explore pentosidine levels as a quantitative measure of aggrecan turnover. In order to compare protein turnover rates, protein residence time was measured as racemization of aspartic acid. As has previously been shown for collagen, pentosidine levels increase with age in cartilage aggrecan. Consistent with the faster turnover of aggrecan compared to collagen, the rate of pentosidine accumulation was threefold lower in aggrecan than in collagen. In the subfractions of aggrecan, pentosidine levels increased with protein residence time. These pentosidine levels were used to estimate the half-life of the globular hyaluronan-binding domain of aggrecan to be 19.5 years. This value is in good agreement with the half-life of 23.5 years that was estimated based on aspartic acid racemization. In aggrecan from osteoarthritic (OA) cartilage, decreased pentosidine levels were found compared with normal cartilage, which reflects increased aggrecan turnover during the OA disease process. In conclusion, we showed that pentosidine accumulates with age in aggrecan and that pentosidine levels can be used as a measure of turnover of long-lived proteins, both during normal aging and during disease.
authors.affiliation: Gaubius Laboratory, TNO Prevention and Health, P.O. Box 2215, 2301 CE, Leiden, The Netherlands.
authors.forename: N
authors.initials: N
authors.lastname: Verzijl
authors.forename: J
authors.initials: J
authors.lastname: DeGroot
authors.forename: R A
authors.initials: RA
authors.lastname: Bank
authors.forename: M T
authors.initials: MT
authors.lastname: Bayliss
authors.forename: J W
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: F P
authors.initials: FP
authors.lastname: Lafeber
authors.forename: A
authors.initials: A
authors.lastname: Maroudas
authors.forename: J M
authors.initials: JM
authors.lastname: TeKoppele
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053674:Aggrecans; D000375:Aging / Q000378:metabolism*; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism*; D002358:Cartilage, Articular / Q000378:metabolism*; D005591:Chemical Fractionation; D002648:Child; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D016326:Extracellular Matrix Proteins; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D037181:Lectins, C-Type; D008239:Lysine / Q000031:analogs & derivatives* / Q000378:metabolism*; D008875:Middle Aged; D010003:Osteoarthritis / Q000378:metabolism / Q000473:pathology; D011509:Proteoglycans / Q000378:metabolism*
chemical_list: D053674:Aggrecans; D011508:Chondroitin Sulfate Proteoglycans; D016326:Extracellular Matrix Proteins; D017127:Glycation End Products, Advanced; D037181:Lectins, C-Type; D011509:Proteoglycans; D001120:Arginine; C062187:pentosidine; D008239:Lysine